Provexis plc (PXS) - Total Liabilities

Latest as of September 2025: GBX230.95K GBX ≈ $28.10 USD

Based on the latest financial reports, Provexis plc (PXS) has total liabilities worth GBX230.95K GBX (≈ $28.10 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is Provexis plc's working capital to evaluate short-term liquidity relative to the company's equity base.

Provexis plc - Total Liabilities Trend (2004–2025)

This chart illustrates how Provexis plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Provexis plc assets under control.

Provexis plc Competitors by Total Liabilities

The table below lists competitors of Provexis plc ranked by their total liabilities.

Company Country Total Liabilities
GETT Gold Inc
V:GETT
Canada CA$18.53 Million
Kavango Resources PLC
LSE:KAV
UK GBX937.00K
Checkit PLC
LSE:CKT
UK GBX8.70 Million
GCL Global Holdings Ltd Warrants
NASDAQ:GCLWW
USA $123.85 Million
SkinBioTherapeutics PLC
LSE:SBTX
UK GBX2.71 Million
International Zeolite Corp
V:IZ
Canada CA$2.88 Million
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
UK GBX3.65 Million
SysGroup PLC
LSE:SYS
UK GBX14.56 Million

Liability Composition Analysis (2004–2025)

This chart breaks down Provexis plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Provexis plc (PXS) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.65 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.20 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Provexis plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Provexis plc (2004–2025)

The table below shows the annual total liabilities of Provexis plc from 2004 to 2025.

Year Total Liabilities Change
2025-03-31 GBX248.21K
≈ $30.20
-19.27%
2024-03-31 GBX307.45K
≈ $37.41
+63.24%
2023-03-31 GBX188.34K
≈ $22.92
+19.27%
2022-03-31 GBX157.91K
≈ $19.21
+4.80%
2021-03-31 GBX150.68K
≈ $18.33
+0.40%
2020-03-31 GBX150.08K
≈ $18.26
+21.87%
2019-03-31 GBX123.14K
≈ $14.98
+37.77%
2018-03-31 GBX89.38K
≈ $10.88
-32.95%
2017-03-31 GBX133.31K
≈ $16.22
+17.20%
2016-03-31 GBX113.75K
≈ $13.84
-0.29%
2015-03-31 GBX114.08K
≈ $13.88
+5.42%
2014-03-31 GBX108.21K
≈ $13.17
-95.61%
2013-03-31 GBX2.47 Million
≈ $299.92
+16.49%
2012-03-31 GBX2.12 Million
≈ $257.46
+275.18%
2011-03-31 GBX564.00K
≈ $68.62
+91.19%
2010-03-31 GBX295.00K
≈ $35.89
+26.07%
2009-03-31 GBX234.00K
≈ $28.47
-35.18%
2008-03-31 GBX361.00K
≈ $43.92
-56.97%
2007-03-31 GBX839.00K
≈ $102.08
+3.97%
2006-03-31 GBX807.00K
≈ $98.19
-14.42%
2005-03-31 GBX943.00K
≈ $114.74
+338.60%
2004-03-31 GBX215.00K
≈ $26.16
--

About Provexis plc

LSE:PXS UK Drug Manufacturers - Specialty & Generic
Market Cap
$308.26K
GBX2.53 Billion GBX
Market Cap Rank
#31229 Global
#990 in UK
Share Price
GBX1.08
Change (1 day)
+0.47%
52-Week Range
GBX0.56 - GBX1.51
All Time High
GBX1.51
About

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and di… Read more